1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Sunridge International, Inc.

Sunridge International, Inc.

SNDZ
Sunridge International, Inc.US flagOther OTC
0.00
USD
- -
- -
4,927.00Market Cap
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.03
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.01
-0.01
-0.01
-0.01
-0.35
-0.33
Tangible Book Value per Share
- -
- -
- -
-0.01
-0.01
-0.02
-0.02
Basic Weighted Avg Shares
19
19
19
19
19
41
45
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-499.53
-569.07
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-691.15
-602.41
Working Capital
- -
- -
- -
- -
- -
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
46
48
Market Capitalization
6
4
2

Working Capital

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
138.17%
296.67%
Free Cash Flow
- -
253.8%
1,179.66%
Net Income, GAAP
- -
689.35%
3,410.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
-0.01
-0.01
-0.01
-0.03
2011
- -
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
G. Richard Smith
Sector
Healthcare
Industry
Medical - Devices
Address
16857 East Saguaro Boulevard Fountain Hills AZ United States of America 85268
IPO Date
Oct 21, 2009
Similar Companies
Drägerwerk AG & Co. KGaA (DRW3.DE)
Dynatronics Corporation (DYNT)
Medacta Group S.A. (0A05.L)
Hyperion DeFi, Inc. (HYPD)
Enovis Corporation (0I1B.L)
China Isotope & Radiation Corporation (1763.HK)
Business
Sunridge International, Inc. (SNDZ) manufactures and markets patented vacuum fixation devices and suction rings for the treatment of open angle and pigmentary glaucoma; through its wholly owned subsidiary Ophthalmic International, Inc., it produces specialized vacuum equipment including molded cases, display boards, circuit boards, and motors for medical applications. The company serves medical supply companies and health care providers worldwide, with operations extending to offices near Phoenix, Arizona, and Rome, Italy. Founded in 1997 and headquartered at 16857 East Saguaro Boulevard in Fountain Hills, Arizona, Sunridge focuses on innovative medical devices within the healthcare sector, targeting ophthalmology treatments. In recent developments, Westhouse Medical Services Plc entered into an asset purchase agreement to acquire substantially all assets of Sunridge International for $2 million, including revolutionary glaucoma treatment and device patents; Sunridge received a $1,000,000 payment from Westhouse as part of this transaction. The company previously appointed a representative in the Middle East and Eastern Europe to expand its distributor network and pursue direct government sales to national health systems. These strategic moves reflect efforts to enhance global market presence amid ongoing operational focus on glaucoma therapies.